Pharma & Healthcare
Adalimumab (Humira) and Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Nov 05, 24
- ID: 660543
- Pages: 123
- Figures: 246
- Views: 13
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
The global market for Adalimumab (Humira) and Biosimilar was estimated to be worth US$ 22420 million in 2023 and is forecast to a readjusted size of US$ 15520 million by 2030 with a CAGR of -5.1% during the forecast period 2024-2030
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Adalimumab (Humira) and Biosimilar, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Adalimumab (Humira) and Biosimilar by region & country, by Type, and by Application.
The Adalimumab (Humira) and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab (Humira) and Biosimilar.
Market Segmentation
By Company
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
Segment by Type:
Syringe
Pen
Segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Adalimumab (Humira) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Adalimumab (Humira) and Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Adalimumab (Humira) and Biosimilar in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Adalimumab (Humira) and Biosimilar was estimated to be worth US$ 22420 million in 2023 and is forecast to a readjusted size of US$ 15520 million by 2030 with a CAGR of -5.1% during the forecast period 2024-2030
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Adalimumab (Humira) and Biosimilar, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Adalimumab (Humira) and Biosimilar by region & country, by Type, and by Application.
The Adalimumab (Humira) and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab (Humira) and Biosimilar.
Market Segmentation
By Company
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
Segment by Type:
Syringe
Pen
Segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Adalimumab (Humira) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Adalimumab (Humira) and Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Adalimumab (Humira) and Biosimilar in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Adalimumab (Humira) and Biosimilar Product Introduction
1.2 Global Adalimumab (Humira) and Biosimilar Market Size Forecast
1.2.1 Global Adalimumab (Humira) and Biosimilar Sales Value (2019-2030)
1.2.2 Global Adalimumab (Humira) and Biosimilar Sales Volume (2019-2030)
1.2.3 Global Adalimumab (Humira) and Biosimilar Sales Price (2019-2030)
1.3 Adalimumab (Humira) and Biosimilar Market Trends & Drivers
1.3.1 Adalimumab (Humira) and Biosimilar Industry Trends
1.3.2 Adalimumab (Humira) and Biosimilar Market Drivers & Opportunity
1.3.3 Adalimumab (Humira) and Biosimilar Market Challenges
1.3.4 Adalimumab (Humira) and Biosimilar Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Adalimumab (Humira) and Biosimilar Players Revenue Ranking (2023)
2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Company (2019-2024)
2.3 Global Adalimumab (Humira) and Biosimilar Players Sales Volume Ranking (2023)
2.4 Global Adalimumab (Humira) and Biosimilar Sales Volume by Company Players (2019-2024)
2.5 Global Adalimumab (Humira) and Biosimilar Average Price by Company (2019-2024)
2.6 Key Manufacturers Adalimumab (Humira) and Biosimilar Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Adalimumab (Humira) and Biosimilar Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Adalimumab (Humira) and Biosimilar
2.9 Adalimumab (Humira) and Biosimilar Market Competitive Analysis
2.9.1 Adalimumab (Humira) and Biosimilar Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Adalimumab (Humira) and Biosimilar Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab (Humira) and Biosimilar as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Syringe
3.1.2 Pen
3.2 Global Adalimumab (Humira) and Biosimilar Sales Value by Type
3.2.1 Global Adalimumab (Humira) and Biosimilar Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Adalimumab (Humira) and Biosimilar Sales Value, by Type (2019-2030)
3.2.3 Global Adalimumab (Humira) and Biosimilar Sales Value, by Type (%) (2019-2030)
3.3 Global Adalimumab (Humira) and Biosimilar Sales Volume by Type
3.3.1 Global Adalimumab (Humira) and Biosimilar Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Adalimumab (Humira) and Biosimilar Sales Volume, by Type (2019-2030)
3.3.3 Global Adalimumab (Humira) and Biosimilar Sales Volume, by Type (%) (2019-2030)
3.4 Global Adalimumab (Humira) and Biosimilar Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Ankylosing Spondylitis
4.1.2 Rheumatoid Arthritis
4.1.3 Crohn’s Disease
4.1.4 Other
4.2 Global Adalimumab (Humira) and Biosimilar Sales Value by Application
4.2.1 Global Adalimumab (Humira) and Biosimilar Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Adalimumab (Humira) and Biosimilar Sales Value, by Application (2019-2030)
4.2.3 Global Adalimumab (Humira) and Biosimilar Sales Value, by Application (%) (2019-2030)
4.3 Global Adalimumab (Humira) and Biosimilar Sales Volume by Application
4.3.1 Global Adalimumab (Humira) and Biosimilar Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Adalimumab (Humira) and Biosimilar Sales Volume, by Application (2019-2030)
4.3.3 Global Adalimumab (Humira) and Biosimilar Sales Volume, by Application (%) (2019-2030)
4.4 Global Adalimumab (Humira) and Biosimilar Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Adalimumab (Humira) and Biosimilar Sales Value by Region
5.1.1 Global Adalimumab (Humira) and Biosimilar Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2019-2024)
5.1.3 Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2025-2030)
5.1.4 Global Adalimumab (Humira) and Biosimilar Sales Value by Region (%), (2019-2030)
5.2 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region
5.2.1 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2019-2024)
5.2.3 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2025-2030)
5.2.4 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (%), (2019-2030)
5.3 Global Adalimumab (Humira) and Biosimilar Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.4.2 North America Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.5.2 Europe Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.6.2 Asia Pacific Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.7.2 South America Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.8.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value
6.2.1 Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.2.2 Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.3.2 United States Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.4.2 Europe Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.5.2 China Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.5.3 China Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.6.2 Japan Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.7.2 South Korea Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.8.2 Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.9.2 India Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.9.3 India Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AbbVie
7.1.1 AbbVie Company Information
7.1.2 AbbVie Introduction and Business Overview
7.1.3 AbbVie Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.1.4 AbbVie Adalimumab (Humira) and Biosimilar Product Offerings
7.1.5 AbbVie Recent Development
7.2 Eisai
7.2.1 Eisai Company Information
7.2.2 Eisai Introduction and Business Overview
7.2.3 Eisai Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Eisai Adalimumab (Humira) and Biosimilar Product Offerings
7.2.5 Eisai Recent Development
7.3 Cadila Healthcare
7.3.1 Cadila Healthcare Company Information
7.3.2 Cadila Healthcare Introduction and Business Overview
7.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Offerings
7.3.5 Cadila Healthcare Recent Development
7.4 Torrent Pharmaceuticals
7.4.1 Torrent Pharmaceuticals Company Information
7.4.2 Torrent Pharmaceuticals Introduction and Business Overview
7.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Offerings
7.4.5 Torrent Pharmaceuticals Recent Development
7.5 Amgen
7.5.1 Amgen Company Information
7.5.2 Amgen Introduction and Business Overview
7.5.3 Amgen Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Amgen Adalimumab (Humira) and Biosimilar Product Offerings
7.5.5 Amgen Recent Development
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Information
7.6.2 Boehringer Ingelheim Introduction and Business Overview
7.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Offerings
7.6.5 Boehringer Ingelheim Recent Development
7.7 Novartis
7.7.1 Novartis Company Information
7.7.2 Novartis Introduction and Business Overview
7.7.3 Novartis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Novartis Adalimumab (Humira) and Biosimilar Product Offerings
7.7.5 Novartis Recent Development
7.8 Samsung Bioepis
7.8.1 Samsung Bioepis Company Information
7.8.2 Samsung Bioepis Introduction and Business Overview
7.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Offerings
7.8.5 Samsung Bioepis Recent Development
7.9 Viatris
7.9.1 Viatris Company Information
7.9.2 Viatris Introduction and Business Overview
7.9.3 Viatris Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Viatris Adalimumab (Humira) and Biosimilar Product Offerings
7.9.5 Viatris Recent Development
7.10 Pfizer
7.10.1 Pfizer Company Information
7.10.2 Pfizer Introduction and Business Overview
7.10.3 Pfizer Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Pfizer Adalimumab (Humira) and Biosimilar Product Offerings
7.10.5 Pfizer Recent Development
7.11 Fresenius Kabi
7.11.1 Fresenius Kabi Company Information
7.11.2 Fresenius Kabi Introduction and Business Overview
7.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Offerings
7.11.5 Fresenius Kabi Recent Development
7.12 Coherus
7.12.1 Coherus Company Information
7.12.2 Coherus Introduction and Business Overview
7.12.3 Coherus Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Coherus Adalimumab (Humira) and Biosimilar Product Offerings
7.12.5 Coherus Recent Development
8 Industry Chain Analysis
8.1 Adalimumab (Humira) and Biosimilar Industrial Chain
8.2 Adalimumab (Humira) and Biosimilar Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Adalimumab (Humira) and Biosimilar Sales Model
8.5.2 Sales Channel
8.5.3 Adalimumab (Humira) and Biosimilar Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Adalimumab (Humira) and Biosimilar Product Introduction
1.2 Global Adalimumab (Humira) and Biosimilar Market Size Forecast
1.2.1 Global Adalimumab (Humira) and Biosimilar Sales Value (2019-2030)
1.2.2 Global Adalimumab (Humira) and Biosimilar Sales Volume (2019-2030)
1.2.3 Global Adalimumab (Humira) and Biosimilar Sales Price (2019-2030)
1.3 Adalimumab (Humira) and Biosimilar Market Trends & Drivers
1.3.1 Adalimumab (Humira) and Biosimilar Industry Trends
1.3.2 Adalimumab (Humira) and Biosimilar Market Drivers & Opportunity
1.3.3 Adalimumab (Humira) and Biosimilar Market Challenges
1.3.4 Adalimumab (Humira) and Biosimilar Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Adalimumab (Humira) and Biosimilar Players Revenue Ranking (2023)
2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Company (2019-2024)
2.3 Global Adalimumab (Humira) and Biosimilar Players Sales Volume Ranking (2023)
2.4 Global Adalimumab (Humira) and Biosimilar Sales Volume by Company Players (2019-2024)
2.5 Global Adalimumab (Humira) and Biosimilar Average Price by Company (2019-2024)
2.6 Key Manufacturers Adalimumab (Humira) and Biosimilar Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Adalimumab (Humira) and Biosimilar Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Adalimumab (Humira) and Biosimilar
2.9 Adalimumab (Humira) and Biosimilar Market Competitive Analysis
2.9.1 Adalimumab (Humira) and Biosimilar Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Adalimumab (Humira) and Biosimilar Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab (Humira) and Biosimilar as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Syringe
3.1.2 Pen
3.2 Global Adalimumab (Humira) and Biosimilar Sales Value by Type
3.2.1 Global Adalimumab (Humira) and Biosimilar Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Adalimumab (Humira) and Biosimilar Sales Value, by Type (2019-2030)
3.2.3 Global Adalimumab (Humira) and Biosimilar Sales Value, by Type (%) (2019-2030)
3.3 Global Adalimumab (Humira) and Biosimilar Sales Volume by Type
3.3.1 Global Adalimumab (Humira) and Biosimilar Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Adalimumab (Humira) and Biosimilar Sales Volume, by Type (2019-2030)
3.3.3 Global Adalimumab (Humira) and Biosimilar Sales Volume, by Type (%) (2019-2030)
3.4 Global Adalimumab (Humira) and Biosimilar Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Ankylosing Spondylitis
4.1.2 Rheumatoid Arthritis
4.1.3 Crohn’s Disease
4.1.4 Other
4.2 Global Adalimumab (Humira) and Biosimilar Sales Value by Application
4.2.1 Global Adalimumab (Humira) and Biosimilar Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Adalimumab (Humira) and Biosimilar Sales Value, by Application (2019-2030)
4.2.3 Global Adalimumab (Humira) and Biosimilar Sales Value, by Application (%) (2019-2030)
4.3 Global Adalimumab (Humira) and Biosimilar Sales Volume by Application
4.3.1 Global Adalimumab (Humira) and Biosimilar Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Adalimumab (Humira) and Biosimilar Sales Volume, by Application (2019-2030)
4.3.3 Global Adalimumab (Humira) and Biosimilar Sales Volume, by Application (%) (2019-2030)
4.4 Global Adalimumab (Humira) and Biosimilar Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Adalimumab (Humira) and Biosimilar Sales Value by Region
5.1.1 Global Adalimumab (Humira) and Biosimilar Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2019-2024)
5.1.3 Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2025-2030)
5.1.4 Global Adalimumab (Humira) and Biosimilar Sales Value by Region (%), (2019-2030)
5.2 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region
5.2.1 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2019-2024)
5.2.3 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2025-2030)
5.2.4 Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (%), (2019-2030)
5.3 Global Adalimumab (Humira) and Biosimilar Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.4.2 North America Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.5.2 Europe Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.6.2 Asia Pacific Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.7.2 South America Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
5.8.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value
6.2.1 Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.2.2 Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.3.2 United States Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.4.2 Europe Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.5.2 China Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.5.3 China Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.6.2 Japan Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.7.2 South Korea Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.8.2 Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Adalimumab (Humira) and Biosimilar Sales Value, 2019-2030
6.9.2 India Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
6.9.3 India Adalimumab (Humira) and Biosimilar Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AbbVie
7.1.1 AbbVie Company Information
7.1.2 AbbVie Introduction and Business Overview
7.1.3 AbbVie Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.1.4 AbbVie Adalimumab (Humira) and Biosimilar Product Offerings
7.1.5 AbbVie Recent Development
7.2 Eisai
7.2.1 Eisai Company Information
7.2.2 Eisai Introduction and Business Overview
7.2.3 Eisai Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Eisai Adalimumab (Humira) and Biosimilar Product Offerings
7.2.5 Eisai Recent Development
7.3 Cadila Healthcare
7.3.1 Cadila Healthcare Company Information
7.3.2 Cadila Healthcare Introduction and Business Overview
7.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Offerings
7.3.5 Cadila Healthcare Recent Development
7.4 Torrent Pharmaceuticals
7.4.1 Torrent Pharmaceuticals Company Information
7.4.2 Torrent Pharmaceuticals Introduction and Business Overview
7.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Offerings
7.4.5 Torrent Pharmaceuticals Recent Development
7.5 Amgen
7.5.1 Amgen Company Information
7.5.2 Amgen Introduction and Business Overview
7.5.3 Amgen Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Amgen Adalimumab (Humira) and Biosimilar Product Offerings
7.5.5 Amgen Recent Development
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Information
7.6.2 Boehringer Ingelheim Introduction and Business Overview
7.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Offerings
7.6.5 Boehringer Ingelheim Recent Development
7.7 Novartis
7.7.1 Novartis Company Information
7.7.2 Novartis Introduction and Business Overview
7.7.3 Novartis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Novartis Adalimumab (Humira) and Biosimilar Product Offerings
7.7.5 Novartis Recent Development
7.8 Samsung Bioepis
7.8.1 Samsung Bioepis Company Information
7.8.2 Samsung Bioepis Introduction and Business Overview
7.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Offerings
7.8.5 Samsung Bioepis Recent Development
7.9 Viatris
7.9.1 Viatris Company Information
7.9.2 Viatris Introduction and Business Overview
7.9.3 Viatris Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Viatris Adalimumab (Humira) and Biosimilar Product Offerings
7.9.5 Viatris Recent Development
7.10 Pfizer
7.10.1 Pfizer Company Information
7.10.2 Pfizer Introduction and Business Overview
7.10.3 Pfizer Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Pfizer Adalimumab (Humira) and Biosimilar Product Offerings
7.10.5 Pfizer Recent Development
7.11 Fresenius Kabi
7.11.1 Fresenius Kabi Company Information
7.11.2 Fresenius Kabi Introduction and Business Overview
7.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Offerings
7.11.5 Fresenius Kabi Recent Development
7.12 Coherus
7.12.1 Coherus Company Information
7.12.2 Coherus Introduction and Business Overview
7.12.3 Coherus Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Coherus Adalimumab (Humira) and Biosimilar Product Offerings
7.12.5 Coherus Recent Development
8 Industry Chain Analysis
8.1 Adalimumab (Humira) and Biosimilar Industrial Chain
8.2 Adalimumab (Humira) and Biosimilar Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Adalimumab (Humira) and Biosimilar Sales Model
8.5.2 Sales Channel
8.5.3 Adalimumab (Humira) and Biosimilar Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Adalimumab (Humira) and Biosimilar Market Trends
Table 2. Adalimumab (Humira) and Biosimilar Market Drivers & Opportunity
Table 3. Adalimumab (Humira) and Biosimilar Market Challenges
Table 4. Adalimumab (Humira) and Biosimilar Market Restraints
Table 5. Global Adalimumab (Humira) and Biosimilar Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Company (2019-2024)
Table 7. Global Adalimumab (Humira) and Biosimilar Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Adalimumab (Humira) and Biosimilar Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Adalimumab (Humira) and Biosimilar Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Adalimumab (Humira) and Biosimilar Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Adalimumab (Humira) and Biosimilar Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Adalimumab (Humira) and Biosimilar
Table 13. Global Adalimumab (Humira) and Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab (Humira) and Biosimilar as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Adalimumab (Humira) and Biosimilar Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Adalimumab (Humira) and Biosimilar Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Adalimumab (Humira) and Biosimilar Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Adalimumab (Humira) and Biosimilar Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Adalimumab (Humira) and Biosimilar Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Adalimumab (Humira) and Biosimilar Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Adalimumab (Humira) and Biosimilar Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Adalimumab (Humira) and Biosimilar Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Adalimumab (Humira) and Biosimilar Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Adalimumab (Humira) and Biosimilar Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Adalimumab (Humira) and Biosimilar Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Adalimumab (Humira) and Biosimilar Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Adalimumab (Humira) and Biosimilar Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Adalimumab (Humira) and Biosimilar Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Adalimumab (Humira) and Biosimilar Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Adalimumab (Humira) and Biosimilar Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Adalimumab (Humira) and Biosimilar Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2019-2024) & (%)
Table 44. Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2025-2030) & (%)
Table 45. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2019-2024) & (%)
Table 49. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2025-2030) & (%)
Table 50. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Volume, (2025-2030) & (K Units)
Table 57. AbbVie Company Information
Table 58. AbbVie Introduction and Business Overview
Table 59. AbbVie Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. AbbVie Adalimumab (Humira) and Biosimilar Product Offerings
Table 61. AbbVie Recent Development
Table 62. Eisai Company Information
Table 63. Eisai Introduction and Business Overview
Table 64. Eisai Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Eisai Adalimumab (Humira) and Biosimilar Product Offerings
Table 66. Eisai Recent Development
Table 67. Cadila Healthcare Company Information
Table 68. Cadila Healthcare Introduction and Business Overview
Table 69. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Offerings
Table 71. Cadila Healthcare Recent Development
Table 72. Torrent Pharmaceuticals Company Information
Table 73. Torrent Pharmaceuticals Introduction and Business Overview
Table 74. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Offerings
Table 76. Torrent Pharmaceuticals Recent Development
Table 77. Amgen Company Information
Table 78. Amgen Introduction and Business Overview
Table 79. Amgen Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Amgen Adalimumab (Humira) and Biosimilar Product Offerings
Table 81. Amgen Recent Development
Table 82. Boehringer Ingelheim Company Information
Table 83. Boehringer Ingelheim Introduction and Business Overview
Table 84. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Offerings
Table 86. Boehringer Ingelheim Recent Development
Table 87. Novartis Company Information
Table 88. Novartis Introduction and Business Overview
Table 89. Novartis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Novartis Adalimumab (Humira) and Biosimilar Product Offerings
Table 91. Novartis Recent Development
Table 92. Samsung Bioepis Company Information
Table 93. Samsung Bioepis Introduction and Business Overview
Table 94. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Offerings
Table 96. Samsung Bioepis Recent Development
Table 97. Viatris Company Information
Table 98. Viatris Introduction and Business Overview
Table 99. Viatris Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Viatris Adalimumab (Humira) and Biosimilar Product Offerings
Table 101. Viatris Recent Development
Table 102. Pfizer Company Information
Table 103. Pfizer Introduction and Business Overview
Table 104. Pfizer Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Pfizer Adalimumab (Humira) and Biosimilar Product Offerings
Table 106. Pfizer Recent Development
Table 107. Fresenius Kabi Company Information
Table 108. Fresenius Kabi Introduction and Business Overview
Table 109. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Offerings
Table 111. Fresenius Kabi Recent Development
Table 112. Coherus Company Information
Table 113. Coherus Introduction and Business Overview
Table 114. Coherus Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Coherus Adalimumab (Humira) and Biosimilar Product Offerings
Table 116. Coherus Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Adalimumab (Humira) and Biosimilar Downstream Customers
Table 120. Adalimumab (Humira) and Biosimilar Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Adalimumab (Humira) and Biosimilar Product Picture
Figure 2. Global Adalimumab (Humira) and Biosimilar Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Adalimumab (Humira) and Biosimilar Sales Volume (2019-2030) & (K Units)
Figure 5. Global Adalimumab (Humira) and Biosimilar Sales Price (2019-2030) & (US$/Unit)
Figure 6. Adalimumab (Humira) and Biosimilar Report Years Considered
Figure 7. Global Adalimumab (Humira) and Biosimilar Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Adalimumab (Humira) and Biosimilar Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Adalimumab (Humira) and Biosimilar Revenue in 2023
Figure 10. Adalimumab (Humira) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Syringe Picture
Figure 12. Pen Picture
Figure 13. Global Adalimumab (Humira) and Biosimilar Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Adalimumab (Humira) and Biosimilar Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Adalimumab (Humira) and Biosimilar Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Adalimumab (Humira) and Biosimilar Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Adalimumab (Humira) and Biosimilar Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Ankylosing Spondylitis
Figure 19. Product Picture of Rheumatoid Arthritis
Figure 20. Product Picture of Crohn’s Disease
Figure 21. Product Picture of Other
Figure 22. Global Adalimumab (Humira) and Biosimilar Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global Adalimumab (Humira) and Biosimilar Sales Value Market Share by Application, 2023 & 2030
Figure 24. Global Adalimumab (Humira) and Biosimilar Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 25. Global Adalimumab (Humira) and Biosimilar Sales Volume Market Share by Application, 2023 & 2030
Figure 26. Global Adalimumab (Humira) and Biosimilar Price by Application (2019-2030) & (US$/Unit)
Figure 27. North America Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 28. North America Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 29. Europe Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 30. Europe Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 31. Asia Pacific Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 33. South America Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 34. South America Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 35. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 36. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 37. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value (%), (2019-2030)
Figure 38. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Volume (%), (2019-2030)
Figure 39. United States Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 40. United States Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 41. United States Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 42. Europe Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 43. Europe Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 44. Europe Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 45. China Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 46. China Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 47. China Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 48. Japan Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 49. Japan Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 50. Japan Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 51. South Korea Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 52. South Korea Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 53. South Korea Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 54. Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 55. Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 56. Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 57. India Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 58. India Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 59. India Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 60. Adalimumab (Humira) and Biosimilar Industrial Chain
Figure 61. Adalimumab (Humira) and Biosimilar Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Table 1. Adalimumab (Humira) and Biosimilar Market Trends
Table 2. Adalimumab (Humira) and Biosimilar Market Drivers & Opportunity
Table 3. Adalimumab (Humira) and Biosimilar Market Challenges
Table 4. Adalimumab (Humira) and Biosimilar Market Restraints
Table 5. Global Adalimumab (Humira) and Biosimilar Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Company (2019-2024)
Table 7. Global Adalimumab (Humira) and Biosimilar Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Adalimumab (Humira) and Biosimilar Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Adalimumab (Humira) and Biosimilar Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Adalimumab (Humira) and Biosimilar Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Adalimumab (Humira) and Biosimilar Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Adalimumab (Humira) and Biosimilar
Table 13. Global Adalimumab (Humira) and Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab (Humira) and Biosimilar as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Adalimumab (Humira) and Biosimilar Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Adalimumab (Humira) and Biosimilar Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Adalimumab (Humira) and Biosimilar Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Adalimumab (Humira) and Biosimilar Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Adalimumab (Humira) and Biosimilar Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Adalimumab (Humira) and Biosimilar Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Adalimumab (Humira) and Biosimilar Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Adalimumab (Humira) and Biosimilar Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Adalimumab (Humira) and Biosimilar Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Adalimumab (Humira) and Biosimilar Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Adalimumab (Humira) and Biosimilar Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Adalimumab (Humira) and Biosimilar Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Adalimumab (Humira) and Biosimilar Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Adalimumab (Humira) and Biosimilar Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Adalimumab (Humira) and Biosimilar Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Adalimumab (Humira) and Biosimilar Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Adalimumab (Humira) and Biosimilar Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Adalimumab (Humira) and Biosimilar Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2019-2024) & (%)
Table 44. Global Adalimumab (Humira) and Biosimilar Sales Value by Region (2025-2030) & (%)
Table 45. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2019-2024) & (%)
Table 49. Global Adalimumab (Humira) and Biosimilar Sales Volume by Region (2025-2030) & (%)
Table 50. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Adalimumab (Humira) and Biosimilar Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Volume, (2025-2030) & (K Units)
Table 57. AbbVie Company Information
Table 58. AbbVie Introduction and Business Overview
Table 59. AbbVie Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. AbbVie Adalimumab (Humira) and Biosimilar Product Offerings
Table 61. AbbVie Recent Development
Table 62. Eisai Company Information
Table 63. Eisai Introduction and Business Overview
Table 64. Eisai Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Eisai Adalimumab (Humira) and Biosimilar Product Offerings
Table 66. Eisai Recent Development
Table 67. Cadila Healthcare Company Information
Table 68. Cadila Healthcare Introduction and Business Overview
Table 69. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Offerings
Table 71. Cadila Healthcare Recent Development
Table 72. Torrent Pharmaceuticals Company Information
Table 73. Torrent Pharmaceuticals Introduction and Business Overview
Table 74. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Offerings
Table 76. Torrent Pharmaceuticals Recent Development
Table 77. Amgen Company Information
Table 78. Amgen Introduction and Business Overview
Table 79. Amgen Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Amgen Adalimumab (Humira) and Biosimilar Product Offerings
Table 81. Amgen Recent Development
Table 82. Boehringer Ingelheim Company Information
Table 83. Boehringer Ingelheim Introduction and Business Overview
Table 84. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Offerings
Table 86. Boehringer Ingelheim Recent Development
Table 87. Novartis Company Information
Table 88. Novartis Introduction and Business Overview
Table 89. Novartis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Novartis Adalimumab (Humira) and Biosimilar Product Offerings
Table 91. Novartis Recent Development
Table 92. Samsung Bioepis Company Information
Table 93. Samsung Bioepis Introduction and Business Overview
Table 94. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Offerings
Table 96. Samsung Bioepis Recent Development
Table 97. Viatris Company Information
Table 98. Viatris Introduction and Business Overview
Table 99. Viatris Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Viatris Adalimumab (Humira) and Biosimilar Product Offerings
Table 101. Viatris Recent Development
Table 102. Pfizer Company Information
Table 103. Pfizer Introduction and Business Overview
Table 104. Pfizer Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Pfizer Adalimumab (Humira) and Biosimilar Product Offerings
Table 106. Pfizer Recent Development
Table 107. Fresenius Kabi Company Information
Table 108. Fresenius Kabi Introduction and Business Overview
Table 109. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Offerings
Table 111. Fresenius Kabi Recent Development
Table 112. Coherus Company Information
Table 113. Coherus Introduction and Business Overview
Table 114. Coherus Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Coherus Adalimumab (Humira) and Biosimilar Product Offerings
Table 116. Coherus Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Adalimumab (Humira) and Biosimilar Downstream Customers
Table 120. Adalimumab (Humira) and Biosimilar Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Adalimumab (Humira) and Biosimilar Product Picture
Figure 2. Global Adalimumab (Humira) and Biosimilar Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Adalimumab (Humira) and Biosimilar Sales Volume (2019-2030) & (K Units)
Figure 5. Global Adalimumab (Humira) and Biosimilar Sales Price (2019-2030) & (US$/Unit)
Figure 6. Adalimumab (Humira) and Biosimilar Report Years Considered
Figure 7. Global Adalimumab (Humira) and Biosimilar Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Adalimumab (Humira) and Biosimilar Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Adalimumab (Humira) and Biosimilar Revenue in 2023
Figure 10. Adalimumab (Humira) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Syringe Picture
Figure 12. Pen Picture
Figure 13. Global Adalimumab (Humira) and Biosimilar Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Adalimumab (Humira) and Biosimilar Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Adalimumab (Humira) and Biosimilar Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Adalimumab (Humira) and Biosimilar Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Adalimumab (Humira) and Biosimilar Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Ankylosing Spondylitis
Figure 19. Product Picture of Rheumatoid Arthritis
Figure 20. Product Picture of Crohn’s Disease
Figure 21. Product Picture of Other
Figure 22. Global Adalimumab (Humira) and Biosimilar Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global Adalimumab (Humira) and Biosimilar Sales Value Market Share by Application, 2023 & 2030
Figure 24. Global Adalimumab (Humira) and Biosimilar Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 25. Global Adalimumab (Humira) and Biosimilar Sales Volume Market Share by Application, 2023 & 2030
Figure 26. Global Adalimumab (Humira) and Biosimilar Price by Application (2019-2030) & (US$/Unit)
Figure 27. North America Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 28. North America Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 29. Europe Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 30. Europe Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 31. Asia Pacific Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 33. South America Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 34. South America Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 35. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Value (2019-2030) & (US$ Million)
Figure 36. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Value by Country (%), 2023 VS 2030
Figure 37. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Value (%), (2019-2030)
Figure 38. Key Countries/Regions Adalimumab (Humira) and Biosimilar Sales Volume (%), (2019-2030)
Figure 39. United States Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 40. United States Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 41. United States Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 42. Europe Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 43. Europe Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 44. Europe Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 45. China Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 46. China Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 47. China Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 48. Japan Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 49. Japan Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 50. Japan Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 51. South Korea Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 52. South Korea Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 53. South Korea Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 54. Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 55. Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 56. Southeast Asia Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 57. India Adalimumab (Humira) and Biosimilar Sales Value, (2019-2030) & (US$ Million)
Figure 58. India Adalimumab (Humira) and Biosimilar Sales Value by Type (%), 2023 VS 2030
Figure 59. India Adalimumab (Humira) and Biosimilar Sales Value by Application (%), 2023 VS 2030
Figure 60. Adalimumab (Humira) and Biosimilar Industrial Chain
Figure 61. Adalimumab (Humira) and Biosimilar Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Shielded Isolator Market Research Report 2025
Jan 25, 25
Global Compressor Nebulizers Market Research Report 2025
Jan 25, 25
Global Electric Mining Truck Market Research Report 2025
Jan 25, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232